Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/cancerbiology.3.038
Efficiency metrics in cancer care
Matt Hickey1, Adele Youngs1, Eduardo Pisani2,*
- 1The Health Value Alliance, Carlton House, 19 West Street, Epsom, Surrey, KT18 7RL, UK
- 2The Health Value Alliance, Carlton House, 19 West Street, Epsom, Surrey, KT18 7RL, UK
- 3All.Can International, Rue du Luxembourg 22-24 BE-1000 Brussels, Belgium
Corresponding Author
Eduardo Pisani, eduardo.pisani@all-can.org
Received Date: August 30, 2022
Accepted Date: September 16, 2022
Hickey M, Youngs A, Pisani E. Efficiency metrics in cancer care. J Cancer Biol. 2022;3(1):16-18.
Copyright: © 2022 Hickey M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Cancer and microenvironment: who and where is the enemy? old problem, new regards
Living cell could be considered the most sophisticated anti-entropy machinery born in the heart of the strong and ferocious pro-entropy environment of the primordial ocean full of boiling and salty water, some thirty-eight hundred million years ago on this planet. Evolution of prokaryotes with a simple cell membrane to eukaryotes and later on multi-cellular organisms, has necessitated the birth and evolution of a protective microenvironment, which could shield and secure evolution of living organisms by its sophisticated anti-entropy components
Efficiency metrics in cancer care
Inefficient care is a leading factor in poorer outcomes for patients. According to the OECD, one-fifth (20%) of healthcare expenditure either does not improve people’s health or could worsen their outcomes [1]. In addition, the World Health Organisation estimates that 40% of health spending is wasted through inefficiency.
Cancer stem cells as a biomarker – A mini review
Cancer stem cells (CSCs) also known as tumor stem cells (TSCs), are pivotal in cancer development and progression. They can be identified through specific markers and surface proteins (e.g., CD44, CD133) that differ from those on non-CSC tumor cells. As well high CSC levels often correlate with poor prognosis, aggressive disease, and resistance to conventional therapies. CSCs are more resistant to standard treatments like chemotherapy and radiation, leading to relapse and metastasis.
Artificial intelligence-augmented breast ultrasound: Advancing diagnostic precision and equity in cancer care-Kuwait
Breast cancer remains the most diagnosed malignancy among women worldwide and continues to be the leading cause of cancer-related deaths. In Kuwait, the disease accounts for 40.1% of all new female cancer cases according to the World Health Organization’s Global Cancer Observatory (2022) [1], reflecting a pressing national health challenge.